Alnylam Pharmaceuticals Inc $ 125.45 -0.21 (-0.17%)
Alnylam Pharmaceuticals Inc News and Headlines -
GlaxoSmithKline (GSK) is betting big that a small San Francisco biotech company can successfully develop a treatment and vaccine against Covid-19. The British pharma giant has made a $250 million equity investment in Vir Biotechnology, Inc. (VIR), hoping Vir’s expertise in monoclonal antibody technology will lead to development of new antibodies that defuse the novel coronavirus.
In late March, Vir said it had identified a number of antibody candidates, two of which the company plans to test in a Phase 2 clinical trial in the next three to five months, according a news release.
Vir’s shares rallied on announcement of
Adopting the theory that two heads are better than one, a pair of former biotech rivals are teaming up to take on a third company that has a head start in the search for a treatment for a genetic disease that can cause lung and liver disease.
Alnylam Pharmaceuticals (ALNY) and Dicerna Pharmaceuticals (DRNA) have joined forces to challenge Arrowhead Pharmaceuticals (ARWR) as well as two other companies working on a treatment, Intellia Therapeutics (NTLA) and Vertex Pharmaceuticals (VRTX).
Evidently, investors believe that a rising tide lifts all boats since shares of all five companies were up Monday, with Arrowhead
BridgeBio, a conglomerate made up of other companies specializing in genetic diseases, plans to go public with a $225 million initial public offering. This comes on the heels of a nearly $300 million financing round in January.
The company will trade on the Nasdaq under the ticker symbol BBIO. The IPO is being underwritten by J.P. Morgan, Goldman Sachs, Piper Jaffary and Mizuho Securities, among others.
Palo Alto, California-based BridgeBio is a four-year-old company that adopted a business model championed by the Sloan Business School of Management at the Massachusetts Institute of Technology. The company finds drugs to treat genetic
Managed by Jason Kritzer and Samantha Pandolfi, the Boston-based fund invests heavily in the health care space. The portfolio managers look around the world for securities that are not only reasonably priced, but which they believe will grow in value over time.
Based on these criteria, the fund opened positions in Alexion Pharmaceuticals Inc. (ALXN), Fisher & Paykel Healthcare Corp. Ltd. (NZSE:FPH), Alnylam Pharmaceuticals Inc. (ALNY), Argenx SE (ARGX) and Sarepta Therapeutics Ltd. (SRPT) during the quarter.
The height of folly.
That’s what I call it when people pay 100 times a company’s pre-share revenue to buy a stock. You see this behavior mostly with young biotechnology stocks and fledgling technology stocks.
Investors mentally build what economics professor Burton Malkiel called “castles in the sky” when they drool over the potential in these stocks.
Of course, it’s possible to luck out if you catch the “next NVidia” but the odds are strongly against you.
Over the years, beginning in 2000, I’ve written 14 columns warning against investing in these sky-high stocks. The stocks I warned against have
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among guru investors.
Eight gurus are invested in Seattle Genetics Inc. (SGEN). The biotech company develops therapies for the treatment of cancer. It has a market cap of $12.41 billion. Its revenue of $575.66 million has climbed 26.40% over a 10-year period.
The stock is trading with a price-book ratio of 8.97. As of Friday, the price of $78 is 2.25% below its 52-week high and 61.34% above its 52-week low. Over the last 10 years, it has returned a gain of 551%.
The company’s largest
After 16 years of development and $2.5 billion in investments, Alnylam Pharmaceuticals Inc. (ALNY) brought the world’s first RNAi treatment, known as Onpattro,Â to market.
Despite this accomplishment, the company did not see a significant jump in its stock following the Food and Drug Administration's approval. In fact, Alnylam is down approximately 6% over the last three months.
Despite the cold market reaction, it is clear Alnylam is promising long term for several reasons. First, RNAi therapies in general show tremendous promise in treating diseases. Second, Alnylam is in the process of
Dodge & Cox, the investment firm founded by Van Duyn Dodge and E. Morris Cox, sold shares of the following stocks in the first quarter.
The firm trimmed its NetApp Inc. (NTAP) position by 96.41%, impacting the portfolio by -0.49%.
The company operates in the design, manufacturing and technical support of high-performance storage and data management solutions. It has a market cap of $18.95 billion and an enterprise value of $15.51 billion.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. Its return on equity of -0.19% and return on
Hope stocks. Fads. Castles in the sky.
Those are the words I think of when I see a stock that sells for 100 times revenue or more. In my view, you almost have to be crazy to invest in them.
Over the years, a typical stock has usually sold for about 1.4 times revenue. In today’s rich market the prevailing ratio is 2.25. So, we’re talking about stocks that sell for 44 times prevailing valuations, which are themselves rich.
The vast majority of these stocks are biotech stocks, and proponents argue that they are worth the inflated multiples. These companies
The fund's Becton, Dickinson and Co. (BDX) holding was closed, impacting the portfolio by -0.64%.
The medical technology company has a market cap of $55.38 billion and an enterprise value of $60.04 billion.
GuruFocus gives the company a profitability and growth rating of 9 out of 10. Its return on equity (ROE) of 10.57% and return on assets (ROA) of 3.70% are outperforming 53% of companies in the Global
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.
Twenty-two gurus are invested in Amgen Inc. (AMGN).
The biotechnology company has a market cap of $131.14 billion. Its revenue has grown 10.50% annually over the past 10 years.
The stock is trading with a price-earnings (P/E) ratio of 16.31. The current stock price of $180.65 is 5.47% below its 52-week high and 20.13% above its 52-week low. Over the past decade, it has returned a gain of 279%.
At the end of last week, Alnylam Pharmaceuticals Inc. (ALNY) announced it had initiated a rolling submission for a new drug application (NDA) rooted in an asset called patisiran. This is a drug that analysts expect could top out at more than $1 billion in annual sales for Alnylam if it is successful in garnering a regulatory greenlight from the U.S. Food and Drug Administration (FDA) and, as such, it is one that markets are keeping an eye on as strongly indicative of wider investor sentiment surrounding the company and its long-term prospects right now.
On the back of the
Analysts have taken action on some health care stocks.
Among the health care companies that saw their stocks re-rated by investment banking and financial services companies are AbbVie (ABBV) and two mid-caps, bluebird bio (BLUE) and Alnylam Pharmaceuticals (ALNY).
The first stock of this short list of re-rated health care companies is AbbVie. According to thefly.com, LEERINK Partners LLC – the health care specialized investment bank – upgraded shares of AbbVie from Market Perform to Outperform.
The U.S. global health care company that was originated in 2013 as Abbott Laboratories’ (ABT) spinoff and headquartered in Lake Bluff, Illinois,
According to GuruFocus' All-in-One Screener, the following are some of the stocks that have outperformed the Standard & Poor's 500 Index over the last 12 months and were bought by gurus during the last quarter.
Albemarle Corp. (ALB) with a market cap of $11.61 billion has outperformed the S&P 500 Index by 10.4% in the last year.
Albemarle manufactures engineered specialty chemicals for various end markets, including petroleum refining, consumer electronics, construction, automotive, lubricants and pharmaceuticals.
Its shares are trading with a price-book (P/B) ratio of 3.19. According to the discount cash flow (DCF) calculator, the company is overpriced
Largest Insider buys for Monsanto (MON), Alnylam Pharmaceuticals Inc. (ALNY), Synergy Resources Corp. (SYRG) and Ferrellgas Partners LP (FGP).
Monsanto Co-Director Charles S. McMillan Bought 3,500 Shares
Director of Monsanto Co. Charles S. McMillan bought 3,500 shares on Oct. 10 at a price of $102.11.
Monsanto is a leading American multinational agrochemical and agricultural biotechnology corporation that specializes in producing genetically engineered seeds. The company has a market cap of $44.68 billion. As of Oct. 14, it traded at $102.11.
On Sep. 14, 2016, the German chemical company Bayer announced that it would take over Monsanto as one of the
Known as the “Father of Value Investing,” Benjamin Graham intelligently invested money in the stock market.
Throughout his investing career, Graham explored several investing strategies to search for company stocks trading at deep prices and discussed the principles of safe investing in his financial books and teachings. During his final three years, the intelligent investor introduced a simple formula for searching bargain stocks: a trailing 12-month price-earnings (P/E) ratio between 7 and 10 and an equity-asset ratio at least 0.5.
Backtesting feature identifies top investing strategies
As discussed in the new feature announcement, the Backtesting feature allows
Much like small-cap stocks, micro-caps offer a chance of a high return, but also present more risk and volatility. Micro-caps are generally defined as companies with a capitalization between $50 million and $300 million.
The All-in-One Screener offers more than 150 filters to sort stocks, including a filter to sort by market cap. The following five stocks were some of the most popular micro-caps purchased by the gurus during the fourth quarter.
Liberty Broadband Corp. (LBRDK)
Liberty Broadband is a holding company that provides digital cable services. Four gurus added to their stakes in the company during the fourth quarter,
According to GuruFocus Insider Data, the largest insider sells during the past week were: Facebook Inc. (FB), PacWest Bancorp (PACW), Waste Management Inc. (WM) and Alnylam Pharmaceuticals Inc. (ALNY).
The overall trend of insiders is illustrated in the chart below:
Facebook Inc.: Director Marc L. Andreessen sold 589,443 shares
Director Marc L. Andreessen sold 589,443 shares during the past week at an average price of $104.04. Andreessen owns at least 167,868 shares after this, and the price of the stock has decreased by 4.3% since.
Facebook has a market cap of $294.22 billion,
He manages a portfolio composed of 48 stocks with a total value of $708 million; the following are the largest trades he did during the second quarter.
He increased his stake in JD.com Inc. (JD) by 632.94% with an impact of 13.04% on his portfolio.
The company is an online direct sales company in China. It provides consumers
As the founder of one of the earliest hedge funds, Julian Robertson (Trades, Portfolio) is a pioneer in the world of investing. Robertson made 16 new buys in the first quarter, two of which were significant enough to join the 10 most valuable stakes in his portfolio. Now retired, Robertson invests in hedge funds that are often run by his former employees.
Robertson's net worth has been estimated at nearly $3.5 billion.
In the first quarter of 2015, he added 16 stakes to his portfolio.
Allergan PLC (AGN), a global pharmaceutical company with headquarters in Dublin, Ireland
|2020-11-25 $ 125.45 (-0.17%)|
Alnylam (ALNY) Gets FDA Nod for Oxlumo to Treat Renal Disease - www.zacks.com
|2020-11-20 $ 124.7 (0.72%)|
Alnylam (ALNY) Gets EU Nod for Oxlumo to Treat Renal Disease - www.zacks.com
|2020-11-09 $ 127.48 (-2.49%)|
Every Stock Tells a Story - www.fool.com
|2020-11-06 $ 130.73 (-5.17%)|
Alnylam's (ALNY) Q3 Loss Wider Than Expected, Revenues Beat - www.zacks.com
|2020-11-05 $ 137.86 (-1.17%)|
|2020-11-04 $ 139.49 (8.09%)|
Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings? - www.zacks.com
Is a Surprise Coming for Alnylam (ALNY) This Earnings Season? - www.zacks.com
|2020-11-03 $ 129.05 (3.31%)|
Vaxart (VXRT) to Report Q3 Earnings: What's in the Cards? - www.zacks.com
What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings? - www.zacks.com
|2020-11-02 $ 124.91 (1.58%)|
What's in Store for Emergent (EBS) This Earnings Season? - www.zacks.com
What's in Store for AstraZeneca (AZN) This Earnings Season? - www.zacks.com
5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates - www.zacks.com
|2020-10-29 $ 123.32 (-1.25%)|
|2020-10-28 $ 124.88 (-1.53%)|
Solid Biosciences (SLDB) to PostQ3 Earnings: What's in Store? - www.zacks.com
Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings? - www.zacks.com
What's in Store for ADMA Biologics' (ADMA) Q3 Earnings? - www.zacks.com
|2020-10-27 $ 126.82 (-1.44%)|
What's in Store for Selecta (SELB) This Earnings Season? - www.zacks.com
Horizon (HZNP) to Report Q3 Earnings: What's in the Cards? - www.zacks.com
Bayer (BAYRY) to Report Q3 Earnings: What's in the Cards? - www.zacks.com
|2020-10-26 $ 128.67 (-2.4%)|
Trevena (TRVN) to Report Q3 Earnings: What's in the Cards? - www.zacks.com
What's in the Cards for Cassava (SAVA) This Earnings Season? - www.zacks.com
Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings? - www.zacks.com
|2020-10-22 $ 134.3 (-1.6%)|
Alexion (ALXN) to Report Q3 Earnings: What's in the Cards? - www.zacks.com
|2020-10-19 $ 140.64 (-3.27%)|
Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran - www.zacks.com
|2020-10-01 $ 143.74 (-1.28%)|
Alnylam Releases Positive Top-Line Rare Disease Lumasiran Data - www.zacks.com
|2020-09-30 $ 145.6 (0.41%)|
|2020-09-15 $ 130.51 (-0.37%)|
Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis - www.zacks.com
|2020-09-09 $ 123.06 (0.06%)|
Why Is Alnylam (ALNY) Down 14.8% Since Last Earnings Report? - www.zacks.com
|2020-08-27 $ 133.05 (%)|
Alnylam's Share Price Rises YTD on Pipeline Developments - www.zacks.com
|2020-08-21 $ 136.6 (0.18%)|
|2020-08-07 $ 143.53 (-0.41%)|
Alnylam (ALNY) Beats on Q2 Earnings, Narrows Sales Guidance - www.zacks.com
|2020-08-06 $ 144.12 (-4.2%)|
|2020-07-30 $ 151.11 (0.37%)|
|2020-07-15 $ 158.02 (0.5%)|
|2020-07-14 $ 157.23 (2.94%)|
Alnylam (ALNY) Upgraded to Buy: Here's Why - www.zacks.com
|2020-07-10 $ 162.25 (2.02%)|
|2020-06-23 $ 151.83 (-0.76%)|
New GERM ETF Launched to Tap the Growing Biotech Sector - www.zacks.com
Is Alnylam a Good Biotech Stock to Buy Now? - www.fool.com
|2020-06-17 $ 136.67 (3.33%)|
Alnylam???s Share Price Rises YTD on Pipeline Developments - www.zacks.com
|2020-06-12 $ 125.39 (-0.41%)|
|2020-06-08 $ 130.44 (2.23%)|
Alnylam Reports Positive Phase III Results on Lumasarin - www.zacks.com
|2020-06-05 $ 127.59 (-3.27%)|
Why Is Alnylam (ALNY) Down 6.8% Since Last Earnings Report? - www.zacks.com
|2020-05-29 $ 135.27 (1.63%)|
|2020-05-27 $ 133.35 (-2.26%)|
Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA - www.zacks.com
|2020-05-25 $ 140.52 (%)|
|2020-05-22 $ 140.52 (-0.94%)|
|2020-05-21 $ 141.86 (-1.11%)|
Is Alnylam Pharmaceuticals a Buy? - www.fool.com
|2020-05-16 $ 139.28 (2.26%)|
|2020-05-11 $ 142.43 (4.63%)|
How Alnylam (ALNY) Stock Stands Out in a Strong Industry - www.zacks.com
|2020-05-08 $ 136.13 (-3.76%)|
|2020-05-07 $ 141.45 (-2.63%)|
What Makes Alnylam (ALNY) a New Buy Stock - www.zacks.com
Alnylam (ALNY) Beats on Q1 Earnings, Cuts Onpattro Sales View - www.zacks.com
|2020-05-06 $ 145.27 (2.86%)|
|2020-05-05 $ 141.23 (3.37%)|
Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards? - www.zacks.com
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More - www.zacks.com
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates - www.zacks.com
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards? - www.zacks.com
|2020-05-04 $ 136.63 (5.94%)|
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards? - www.zacks.com
Teva (TEVA) to Report Q1 Earnings: What's in the Cards? - www.zacks.com
|2020-04-29 $ 135.81 (-1.23%)|
BioCryst (BCRX) to Report Q1 Earnings: What's in the Cards? - www.zacks.com
|2020-04-28 $ 137.5 (-3.64%)|
Is a Beat in Store for Avadel (AVDL) This Earnings Season? - www.zacks.com
What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings? - www.zacks.com
|2020-04-27 $ 142.7 (-2.01%)|
What's in Store for Aytu BioScience's (AYTU) Q3 Earnings? - www.zacks.com
|2020-04-24 $ 145.63 (2.82%)|
Will Gilead (GILD) Beat Q1 Earnings Despite Coronavirus Mayhem? - www.zacks.com
Is a Beat in Store for Abeona (ABEO) This Earnings Season? - www.zacks.com
|2020-04-22 $ 140.11 (1.64%)|
|2020-04-15 $ 121.5 (0.65%)|
Alnylam's Vutrisiran Gets Fast Track Tag for hATTR Amyloidosis - www.zacks.com
2 Top Small-Cap Stocks to Buy Right Now - www.fool.com
|2020-04-14 $ 120.72 (1.44%)|
Alnylam's $2B Deal With Blackstone to Boost Drug Development - www.zacks.com
|2020-04-13 $ 119.01 (2.26%)|
Alnylam Scores a $2 Billion Investment From Blackstone - www.fool.com
Better Buy: Alnylam Pharmaceuticals vs. Vir Biotechnology - www.fool.com
|2020-04-08 $ 111.39 (1.71%)|
Alnylam (ALNY) Completes Rolling Submission of Lumasiran NDA - www.zacks.com
|2020-04-07 $ 109.52 (-2.34%)|
Glaxo to Buy Stake in Vir Biotech, Signs Coronavirus Deal - www.zacks.com
|2020-04-06 $ 112.14 (5.97%)|
Alnylam, Dicerna Join Forces to Take on Arrowhead - GuruFocus.com
|2020-02-24 $ 122.29 (-6.67%)|
|2020-02-21 $ 131.03 (-1.57%)|
|2020-02-14 $ 128.7 (-1.08%)|